

Check-Cap Ltd  
Form 6-K  
February 12, 2019

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For February 2019

Commission File No. 001-36848

Check-Cap Ltd.

---

Check-Cap Building  
Abba Hushi Avenue  
P.O. Box 1271  
Isfiya, 30090  
Mount Carmel, Israel  
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES.)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F    Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

This Form 6-K is being incorporated by reference into the Post-Effective Amendment No. 1 to the Form S-8 Registration Statement File No. 333-203384, Form S-8 Registration Statement File No. 333-226490, and into the Form F-3 Registration Statements File Nos. 333-211065 and 333-225789.

---

Other Information

On February 12, 2019, Check-Cap Ltd. issued a press release announcing it received Institutional Review Board (IRB) approval from the New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit

Exhibit No. Description

99.1            Press Release, dated February 12, 2019

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Check-Cap Ltd.

By: /s/ Alex Ovadia

Name: Alex Ovadia

Date: February 12, 2019

Title: Chief Executive Officer

---